View Item 

Show simple item record

Future of preventing and managing common chronic inflammatory diseases
dc.contributor.authorKornman, Kenneth S.
dc.date.accessioned2020-11-04T16:00:10Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-11-04T16:00:10Z
dc.date.issued2020-10
dc.identifier.citationKornman, Kenneth S. (2020). "Future of preventing and managing common chronic inflammatory diseases." Journal of Periodontology 91: S12-S18.
dc.identifier.issn0022-3492
dc.identifier.issn1943-3670
dc.identifier.urihttps://hdl.handle.net/2027.42/163431
dc.description.abstractChronic inflammation has emerged as a key factor that contributes to some common chronic diseases and reduces lifespan. Studies have identified multiple types of chronic inflammation ranging from autoimmune disease, which attacks specific tissues, to autoinflammatory diseases, which cause low‐grade systemic inflammation and contribute to several common chronic diseases. This article highlights new perspectives on the role of chronic inflammation in cardiovascular disease (CVD). Such information is being leveraged to develop new treatment strategies for CVD and may inform how periodontal disease influences CVD.
dc.publisherWiley Periodicals, Inc.
dc.publisherElsevier Saunders
dc.subject.otherC‐reactive protein
dc.subject.otherinflammation
dc.subject.othercardiovascular disease
dc.subject.otherperiodontal disease
dc.subject.otherperiodontitis
dc.subject.otherinflammatory disease
dc.titleFuture of preventing and managing common chronic inflammatory diseases
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163431/2/jper10590.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163431/1/jper10590_am.pdfen_US
dc.identifier.doi10.1002/JPER.20-0134
dc.identifier.sourceJournal of Periodontology
dc.identifier.citedreferenceDiCesare PE, Abramson SB. Pathogenesis of osteoarthritis. In: Harris DE, Budd RC, Genovese MC, Firestein GS, Sargeni JS, Sledge CB, eds. Kelly’s Textbook of Rheumatology. New York, NY: Elsevier Saunders; 2005: 1493 ‐ 1513.
dc.identifier.citedreferenceOtterness IG. The value of C‐reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 1994; 24: 91 ‐ 104.
dc.identifier.citedreferenceDinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin‐1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012; 11: 633 ‐ 652.
dc.identifier.citedreferenceAday AW, Ridker PM. Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front Cardiovasc Med. 2019; 6: 16.
dc.identifier.citedreferenceLibby P. Interleukin‐1 Beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017; 70: 2278 ‐ 2289.
dc.identifier.citedreferenceMaedler K, Sergeev P, Ris F, et al. Glucose‐induced beta cell production of IL‐1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002; 110: 851 ‐ 860.
dc.identifier.citedreferenceWu X, Kondragunta V, Kornman KS, et al. IL‐1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthritis Cartilage. 2013; 21: 930 ‐ 938.
dc.identifier.citedreferenceRidker PM. Anti‐inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. J Intern Med. 2019; 285: 503 ‐ 509.
dc.identifier.citedreferenceRidker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin‐6 signalling pathway and incidence rates of atherosclerotic events and all‐cause mortality: analyses from the Canakinumab Anti‐Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018; 39: 3499 ‐ 3507.
dc.identifier.citedreferenceSabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713 ‐ 1722.
dc.identifier.citedreferenceMurphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019; 4: 613 ‐ 619.
dc.identifier.citedreferenceViney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double‐blind, placebo‐controlled, dose‐ranging trials. Lancet. 2016; 388: 2239 ‐ 2253.
dc.identifier.citedreferenceHajishengallis G, Lamont RJ, Graves DT. The enduring importance of animal models in understanding periodontal disease. Virulence. 2015; 6 ( 3 ): 229 ‐ 235.
dc.identifier.citedreferenceGraves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. J Oral Microbiol. 2011; 3.
dc.identifier.citedreferenceGraves DT, Cochran D. The contribution of interleukin‐1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol. 2003; 74: 391 ‐ 401.
dc.identifier.citedreferenceDelima AJ, Karatzas S, Amar S, Graves DT. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin‐1 antagonists. J Infect Dis. 2002; 186: 511 ‐ 516.
dc.identifier.citedreferenceCheng R, Wu Z, Li M, Shao M, Hu T. Interleukin‐1beta is a potential therapeutic target for periodontitis: a narrative review. Int J Oral Sci. 2020; 12: 2.
dc.identifier.citedreferenceParaskevas S, Huizinga JD, Loos BG. A systematic review and meta‐analyses on C‐reactive protein in relation to periodontitis. J Clin Periodontol. 2008; 35: 277 ‐ 290.
dc.identifier.citedreferenceNoack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C‐reactive protein level. J Periodontol. 2001; 72: 1221 ‐ 1227.
dc.identifier.citedreferenceLoos BG, Craandijk J, Hoek FJ, Wertheim‐van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol. 2000; 71: 1528 ‐ 1534.
dc.identifier.citedreferenceDinarello CA. A clinical perspective of IL‐1beta as the gatekeeper of inflammation. Eur J Immunol. 2011; 41: 1203 ‐ 1217.
dc.identifier.citedreferenceDregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population‐based cohort study. Circulation. 2014; 130: 837 ‐ 844.
dc.identifier.citedreferenceRidker PM, Hennekens CH, Buring JE, Rifai N. C‐reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836 ‐ 843.
dc.identifier.citedreferenceRidker PM. Clinical application of C‐reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107: 363 ‐ 369.
dc.identifier.citedreferenceRidker PM, Cannon CP, Morrow D, et al. C‐reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20 ‐ 28.
dc.identifier.citedreferenceRidker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med. 2008; 359: 2195 ‐ 2207.
dc.identifier.citedreferenceRidker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377: 1119 ‐ 1131.
dc.identifier.citedreferenceLibby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019; 74: 1594 ‐ 1607.
dc.identifier.citedreferenceRidker PM. High‐sensitivity C‐reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004; 148: S19 ‐ S26.
dc.identifier.citedreferenceBoffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016; 57: 745 ‐ 757.
dc.identifier.citedreferenceTsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005; 353: 46 ‐ 57.
dc.identifier.citedreferenceNordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016; 57: 1953 ‐ 1975.
dc.identifier.citedreferenceTsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)‐Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018; 71: 177 ‐ 192.
dc.identifier.citedreferenceLibby P. Molecular bases of the acute coronary syndromes. Circulation. 1995; 91: 2844 ‐ 2850.
dc.identifier.citedreferenceLibby P, Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018; 72: 2071 ‐ 2081.
dc.identifier.citedreferenceLibby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin‐1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986; 78: 1432 ‐ 1438.
dc.identifier.citedreferenceTsimikas S. A test in context: lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017; 69: 692 ‐ 711.
dc.identifier.citedreferenceNaka KK, Bechlioullis A, Marini A, et al. Interleukin‐1 genotypes modulate the long‐term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. J Clin Lipidol. 2018; 12: 338 ‐ 347.
dc.identifier.citedreferenceTsimikas S, Duff GW, Berger PB, et al. Pro‐inflammatory interleukin‐1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014; 63: 1724 ‐ 1734.
dc.identifier.citedreferenceNaghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108: 1664 ‐ 1672.
dc.identifier.citedreferenceRidker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc. 2013; 124: 174 ‐ 190.
dc.identifier.citedreferenceRidker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep. 2013; 15: 295.
dc.identifier.citedreferenceRidker PM. Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J Am Coll Cardiol. 2018; 72: 3320 ‐ 3331.
dc.identifier.citedreferenceRidker PM, Thuren T, Zalewski A, Libby P. Interleukin‐1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti‐inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162: 597 ‐ 605.
dc.identifier.citedreferenceEverett BM, Cornel JH, Lainscak M, et al. Anti‐inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019; 139: 1289 ‐ 1299.
dc.identifier.citedreferenceRidker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin‐1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double‐blind, placebo‐controlled trial. Lancet. 2017; 390: 1833 ‐ 1842.
dc.identifier.citedreferenceRidker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of interleukin‐1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018; 71: 2405 ‐ 2414.
dc.identifier.citedreferenceBell CL, Chen R, Masaki K, et al. Late‐life factors associated with healthy aging in older men. J Am Geriatr Soc. 2014; 62: 880 ‐ 888.
dc.identifier.citedreferenceMcGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006; 3: e297.
dc.identifier.citedreferenceChetaille Nezondet AL, Poubelle PE, Pelletier M. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases. J Leukoc Biol. 2020.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jper10590_am.pdf
Size:
888.6KB
Format:
PDF
View/Open
Name:
jper10590.pdf
Size:
820.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.